載入中
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
前收盤價
US$1.34
−US$0.04 · -2.90%
盤前
US$1.417
+US$0.077 · +5.75%
10月12日 上午7:03 ET
盤中時間採用ET。市場資料可能有所延遲。
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
日內區間
目前US$1.34
52週區間
目前US$1.34
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
48
合理估值
情緒
41
多空交錯
風險
69
高風險
動能
30
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
日內區間
目前US$1.34
52週區間
目前US$1.34
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 250.1萬 USD | — | 250.1萬 USD | — | — |
| 毛利 | −250.1萬 USD | — | −250.1萬 USD | — | — |
| 研究與開發 | 1021.1萬 USD | 1696.2萬 USD | 1682.7萬 USD | 1406.2萬 USD | 734.7萬 USD |
| 銷售、一般及管理費用 | 965萬 USD | 1263.7萬 USD | 1351萬 USD | 1445.9萬 USD | 730.6萬 USD |
| 營業費用 | 1736萬 USD | 3043.7萬 USD | 2783.6萬 USD | 2852.1萬 USD | 1465.3萬 USD |
| 利息收入 | 42.1萬 USD | 23萬 USD | — | — | — |
| 折舊和攤銷 | 250.1萬 USD | 265.5萬 USD | 250.1萬 USD | 110.3萬 USD | 78.8萬 USD |
| 營業利益 | −1986.1萬 USD | −3043.7萬 USD | −3033.7萬 USD | −2852.1萬 USD | −1465.3萬 USD |
| 淨利 | −1944萬 USD | −3043.7萬 USD | −3000.7萬 USD | −2852.1萬 USD | −1465.3萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.00
上漲空間 198.51%價格歷史記錄不可用
最高：US$4.00平均的：US$4.00最低：US$4.00評級樣本有限，僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年6月6日 | 1:30 | — | — |
已生效 2025年6月6日
1:30
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
